---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-064469"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:17:08.006497+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company

## Summary
- Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.
- Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.
- Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.
- Andrew Oakley elected Lead Independent Director, to receive $36,000/month.
- Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026.

## SEC filing metadata
- accession: 0001213900-25-064469
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/0001213900-25-064469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/ea0248815-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-064469
- JSON: https://secwatch.observer/filing/0001213900-25-064469.json
- Plain text: https://secwatch.observer/filing/0001213900-25-064469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.